Whitehawk Therapeutics (NASDAQ:WHWK) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Whitehawk Therapeutics (NASDAQ:WHWK) from a "hold" to a "sell", while analyst coverage is mixed (two Buys, one Hold, one Sell) and MarketBeat's consensus remains a Hold with a $6.50 price target.
• CEO David James Lennon sold 102,395 shares at an average $3.51 (~$359,406) to cover tax withholding, and insiders have sold 311,313 shares in the past 90 days while still owning about 49.9% of the stock.
• Shares opened at $3.39 with a market cap of $160 million, a 52‑week range of $1.39–$4.48, and the company reported a quarterly EPS of ($0.34) versus estimates of ($0.55), beating expectations by $0.21.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Other analysts have also recently issued research reports about the stock. JonesTrading started coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a "buy" rating and a $7.00 price target on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Finally, Oppenheimer began coverage on Whitehawk Therapeutics in a research note on Thursday, February 5th. They issued an "outperform" rating and a $6.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $6.50.

Whitehawk Therapeutics Stock Performance

Whitehawk Therapeutics stock opened at $3.39 on Friday. The firm has a market cap of $160.01 million, a price-to-earnings ratio of 7.21 and a beta of 0.57. Whitehawk Therapeutics has a 52-week low of $1.39 and a 52-week high of $4.48. The firm has a 50 day moving average price of $3.35 and a two-hundred day moving average price of $2.71.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.21.

Insider Activity

In related news, CEO David James Lennon sold 102,395 shares of the business's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $3.51, for a total transaction of $359,406.45. Following the transaction, the chief executive officer owned 691,154 shares in the company, valued at $2,425,950.54. The trade was a 12.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 311,313 shares of company stock worth $1,073,551. 49.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of large investors have recently bought and sold shares of WHWK. Quadrature Capital Ltd acquired a new position in shares of Whitehawk Therapeutics during the fourth quarter valued at about $28,000. ABG Innovation Capital Partners III GP Ltd bought a new stake in Whitehawk Therapeutics in the 3rd quarter valued at about $51,000. Dimensional Fund Advisors LP bought a new stake in Whitehawk Therapeutics in the 3rd quarter valued at about $84,000. Squarepoint Ops LLC acquired a new position in Whitehawk Therapeutics during the 3rd quarter worth approximately $159,000. Finally, Marshall Wace LLP acquired a new position in Whitehawk Therapeutics during the 4th quarter worth approximately $164,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.